FDA Acceptance of Medicines360’s Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Application Seeks to Extend Duration of Use Up to 5 Years for LILETTA DUBLIN and SAN FRANCISCO – Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s […]
Study Finds Z-CAN Program, Supported by Medicines360, Increased Use of LARCs by Women in Puerto Rico During Zika Outbreak
Access to Full Range of Contraception, Plus Patient-Centered Counseling, Successful Formula for Woman-led Prevention of Unintended Pregnancy SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health. The report examined the effectiveness of the CDC […]
[Journal of Contraception] Bleeding patterns do not differ between obese and non-obese women using a levonorgestrel 52 mg intrauterine system
[Journal of Contraception] Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use
FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years
Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN and SAN FRANCISCO – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use […]
Medicines360 and Allergan Present Four-Year Multi-Center Pivotal Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at the 2017 ACOG Meeting
Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, presented four-year data from their ongoing multi-center U.S.-based pivotal trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at the American College of Obstetricians and Gynecologists (ACOG) annual clinical and scientific meeting.
[Journal of Obstetrics & Gynecology] Four-year efficacy and safety of the Liletta™ levonorgestrel intrauterine system
Medicines360 and Allergan Announce Partnership with Health Centers to Help Address Unintended Pregnancies in Areas Impacted by Zika
Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced a partnership with 340B-eligible health centers and other safety net providers in Puerto Rico and Florida, both areas where there is local transmission of the Zika virus, to make available their hormonal contraceptive, LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg. LILETTA is an IUS, intrauterine system (otherwise known as an intrauterine device or IUD), that is approved for the prevention of pregnancy for up to three years.
FDA Accepts for Filing Supplemental New Drug Application (sNDA) for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a nonprofit global women’s health pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) to potentially extend the duration of use for the prevention of pregnancy from up to three years to up to four years for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg.
Medicines360 and Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing and LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Placement
Medicines360, a nonprofit global women’s health pharmaceutical company, and Allergan, plc (NYSE: AGN), a leading global pharmaceutical company, today announced the publication of, “A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement” in the November, 2016 medical journal, American Journal of Obstetrics & Gynecology.
